CONTEXT: Publication of a retrospective chart review on the effectiveness of Halaven (eribulin mesylate) in metastatic breast cancer | One of the limitations of this study is that detailed safety data were not collected | US only data
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “Of the patients who discontinued treatment with HALAVEN, disease progression was reported as the main reason for 78.1% and 84.3% of patients in the overall cohort and TNBC subtype, respectively.”
2. “WOODCLIFF LAKE, N.J., May 18, 2021 /PRNewswire/ — Eisai today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients with metastatic breast cancer (mBC), including the triple-negative breast cancer (TNBC) subtype.”
3. “At the time of data cut-off, 96.9% (n=497) in the overall patient cohort and 96.9% (n=248) in the TNBC subgroup had discontinued HALAVEN treatment.”
4. “About HALAVEN® (eribulin mesylate) Injection. HALAVEN (eribulin mesylate) injection is indicated for the treatment of patients with metastatic breast cancer (mBC) who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease.”
5. “Adverse Reactions. In patients with mBC receiving HALAVEN, the most common adverse reactions (≥25%) were neutropenia (82%), anemia (58%), asthenia/fatigue (54%), alopecia (45%), peripheral neuropathy (35%), nausea (35%), and constipation (25%).”